Gemcitabine News
Addition of Gemzar® to Taxotere® Improves Survival as Initial Therapy in Non–Small Cell Lung Cancer
According to an early online article in Lung Cancer, the addition of Gemzar® (gemcitabine) to Taxotere® (docetaxel) improves survival compared with Taxotere only when used as initial therapy in patients with advanced non–small...
Gemcitabine Plus Paclitaxel May Be Effective Treatment for Metastatic Breast Cancer: Presented at ASCO-Breast Cancer
Results of a phase 3 study suggest that gemcitabine plus paclitaxel may provide an effective treatment option for unresectable, locally recurrent, or metastatic breast cancer, investigators say.
Addition of Tarceva® to Gemzar® Improves Survival in Pancreatic Cancer
According to an early online publication in the Journal of Clinical Oncology, the addition of the targeted agent Tarceva® (erlotinib) to Gemzar® (gemcitabine) improves survival in patients with advanced pancreatic cancer.
ONC Oncolytics drug combination kills colon cancer in mouse
ONCOLYTICS BIOTECH INC. COLLABORATORS TO PRESENT REOVIRUS/GEMCITABINE COMBINATION RESEARCH AT AACR ANNUAL MEETING
Chemotherapy Plus Chemoradiation Post-Surgery Produces 71% Survival in Pancreatic Cancer: Presented at GASTRO 2007
Pancreatic cancer patients who had chemotherapy as well as chemoradiation after potentially curative surgery achieved a 71% 1-year rate of recurrence-free survival, researchers reported here at the 2007 Gastrointestinal Cancers...